Systematic review and meta-analysis demonstrate dose-response effects of cell therapy on pain and quality of life in osteoarthritis, suggesting future prospective studies are needed.
Based on the findings of this meta-analysis, BM-MSCs, especially in the long term, can be effective in reducing pain, stiffness, and improving the quality of life of patients with osteoarthritis. Also, the favorable safety of these cells makes them a promising option in joint reconstruction treatments. However, due to the heterogeneity of studies and the lack of standardized information on the optimal dose, it seems necessary to conduct prospective studies with careful design and long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Lohrasbi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: